SCHEMBL6038562

SCHEMBL6038562

CCc1ccc(S(=O)(=O)Nc2nccnc2OCCc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 3/20 0.48
MAPT P10636 2/20 0.46
CCR2 P41597 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALOX12 P18054 1/20 0.43
GAA P10253 2/20 0.42
EDNRB P24530 1/20 0.42
EDNRA P25101 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
UCHL1 P09936 1/20 0.42
MCL1 Q07820 1/20 0.42
BCL2A1 Q16548 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038918 0.89 AR (0.49) KMT2AL3MBTL1MEN1CCR2ALDH1A1
SCHEMBL6038515 0.88 KMT2A (0.49) KMT2AL3MBTL1MEN1MAPTCCR2
SCHEMBL6038900 0.88 KMT2A (0.53) KMT2AMEN1MAPTCCR2ALDH1A1
SCHEMBL6039037 0.87 MYLK (0.51) KMT2AMEN1MAPTCCR2ALDH1A1
SCHEMBL6038939 0.87 AR (0.49) KMT2AL3MBTL1MEN1CCR2ALDH1A1
SCHEMBL6038820 0.84 KMT2A (0.45) KMT2AL3MBTL1MEN1MAPTALDH1A1
SCHEMBL6038452 0.84 MEN1 (0.46) KMT2AL3MBTL1MEN1MAPTCCR2
SCHEMBL6039018 0.84 KMT2A (0.66) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL6039097 0.84 MEN1 (0.48) KMT2AL3MBTL1MEN1CCR2ALDH1A1
SCHEMBL6039119 0.84 PTGDR2 (0.52) KMT2AL3MBTL1MEN1MAPTCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 KMT2A 4190/4885L3MBTL1 2666/4885MEN1 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.